FUSION-Guided Hypothesis Development Leads to the Identification of N6,N6-Dimethyladenosine, a Marine-Derived AKT Pathway Inhibitor
Chemicals found in nature have evolved over geological time scales to productively interact with biological molecules, and thus represent an effective resource for pharmaceutical development. Marine-derived bacteria are rich sources of chemically diverse, bioactive secondary metabolites, but harness...
Main Authors: | Rachel M. Vaden, Nathaniel W. Oswald, Malia B. Potts, John B. MacMillan, Michael A. White |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2017-03-01
|
Series: | Marine Drugs |
Subjects: | |
Online Access: | http://www.mdpi.com/1660-3397/15/3/75 |
Similar Items
-
PCIF1, the only methyltransferase of N6,2-O-dimethyladenosine
by: Yuting Wu, et al.
Published: (2023-10-01) -
DLm6Am: A Deep-Learning-Based Tool for Identifying N6,2′-O-Dimethyladenosine Sites in RNA Sequences
by: Zhengtao Luo, et al.
Published: (2022-09-01) -
Identification of N[superscript 6],N[superscript 6]-Dimethyladenosine in Transfer RNA from Mycobacterium bovis Bacille Calmette-Guérin
by: Chan, Tsz Yan Clement, et al.
Published: (2014) -
RNA modification m6Am: the role in cardiac biology
by: Daniel Benak, et al.
Published: (2023-12-01) -
Gene signatures, immune infiltration, and drug sensitivity based on a comprehensive analysis of m6a RNA methylation regulators in cervical cancer
by: Xiaoqin Lu, et al.
Published: (2022-09-01)